Cetera Advisor Networks LLC Editas Medicine, Inc. Transaction History

Cetera Advisor Networks LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$6.25 - $11.11 $70,481 - $125,287	11,277 New	11,277 $114,000
Q2 2022 Aug 11, 2022	BUY	$9.99 - $21.35 $103,806 - $221,847	10,391 New	10,391 $123,000
Q4 2021 Feb 14, 2022	SELL	$26.55 - $40.57 $230,108 - $351,620	-8,667 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$39.27 - $72.94 $26,350 - $48,942	671 Added 8.39%	8,667 $356,000
Q2 2021 Aug 13, 2021	SELL	$31.29 - $56.64 $183,547 - $332,250	-5,866 Reduced 42.32%	7,996 $453,000
Q1 2021 May 17, 2021	BUY	$39.71 - $90.58 $359,613 - $820,292	9,056 Added 188.43%	13,862 $582,000
Q4 2020 Feb 17, 2021	BUY	$27.07 - $84.35 $130,098 - $405,386	4,806 New	4,806 $337,000
Q3 2020 Nov 13, 2020	SELL	$28.06 - $37.16 $70,655 - $93,568	-2,518 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$18.5 - $34.34 $46,583 - $86,468	2,518 New	2,518 $74,000

244

56.8M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Cetera Advisor Networks LLC, based on Form 13F filings with the SEC.

Stay updated on Cetera Advisor Networks LLC with notifications on news.